Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Keyphrases

• Chemotherapy 100%
• Preoperative Chemotherapy 100%
• After Surgery 100%
• Chemoradiotherapy 100%
• Randomized Phase III Trial 100%
• Resectable Gastric Cancer 100%
• Concurrent Chemoradiotherapy 41%
• Adverse Events 25%
• Cisplatin 25%
• Epirubicin 25%
• Twice Daily 25%
• Postoperative Treatment 25%
• Dutch 16%
• Overall Survival 16%
• Treatment Strategy 16%
• Oxaliplatin 16%
• Capecitabine 16%
• Preoperative Treatment 16%
• Radiotherapy 8%
• Netherlands 8%
• Europe 8%
• Primary Tumor 8%
• Bone Marrow 8%
• Colorectal Cancer 8%
• Hazard Ratio 8%
• Kidney Function 8%
• EudraCT 8%
• Median Overall Survival 8%
• Intention-to-treat 8%
• North America 8%
• Cause of Death 8%
• Radiation Therapy 8%
• Diarrhea 8%
• Chemotherapy Treatment 8%
• Treatment Group 8%
• Febrile Neutropenia 8%
• Tumor Localization 8%
• Sweden 8%
• Denmark 8%
• Histological Subtypes 8%
• Treatment Allocation 8%
• Radical Resection 8%
• Liver Function 8%
• Cardiovascular Events 8%
• Lymph Node Dissection 8%
• WHO Performance Status 8%
• Investigator-initiated 8%
• American Joint Committee on Cancer 8%
• Sudden Death 8%
• Stratified Analysis 8%
• Patient-assessed 8%
• Postoperative Patients 8%
• Stage IB 8%
• Head-to-head Comparison 8%
• Preoperative Surgery 8%
• Curative Resection 8%
• Gastroesophageal Adenocarcinoma 8%
• Random Element 8%
• Dihydropyrimidine 8%
• Resectable Gastric Adenocarcinoma 8%
• Functional Bowel Disorders 8%
• Patient Compliance 8%

Medicine and Dentistry

• Preoperative Chemotherapy 100%
• Chemoradiotherapy 100%
• Stomach Cancer 100%
• Adverse Event 21%
• Overall Survival 21%
• Cisplatin 21%
• Epirubicin 21%
• Postoperative Care 21%
• Malignant Neoplasm 14%
• Radiation Therapy 14%
• Capecitabine 14%
• Preoperative Treatment 14%
• Oxaliplatin 14%
• Primary Tumor 7%
• Surgery 7%
• Colorectal Cancer 7%
• Hazard Ratio 7%
• Group Therapy 7%
• Kidney Function 7%
• Intention-to-Treat Analysis 7%
• Diarrhea 7%
• Febrile Neutropenia 7%
• Tumor Localization 7%
• Patient Compliance 7%
• Esophageal Adenocarcinoma 7%
• Retroperitoneal Lymph Node Dissection 7%
• Radical Resection 7%
• Cardiovascular System 7%
• Bowel Obstruction 7%
• Liver Function 7%
• Sudden Death 7%
• Stomach Adenocarcinoma 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Chemoradiation Therapy 100%
• Stomach Cancer 100%
• Overall Survival 14%
• Epirubicin 14%
• Cisplatin 14%
• Adverse Event 14%
• Malignant Neoplasm 9%
• Oxaliplatin 9%
• Capecitabine 9%
• Tablet 9%
• Neoplasm 4%
• Primary Tumor 4%
• Colorectal Cancer 4%
• Diarrhea 4%
• Febrile Neutropenia 4%
• Esophageal Adenocarcinoma 4%
• Intestine Obstruction 4%
• Stomach Adenocarcinoma 4%
• Sudden Death 4%